Review

The combination of histone deacetylase inhibitors and radiotherapy: a promising novel approach for cancer treatment

https://orcid.org/0000-0001-8190-8106

Institute of Pharmaceutical Sciences, Guru Ghasidas University, Bilaspur-495 009, Chhattisgarh, India

Search for more papers by this author

Preeti Patel

https://orcid.org/0000-0003-1606-2241

Institute of Pharmaceutical Sciences, Guru Ghasidas University, Bilaspur-495 009, Chhattisgarh, India

Search for more papers by this author

Vijay K Patel

https://orcid.org/0000-0002-0392-3308

Institute of Pharmaceutical Sciences, Guru Ghasidas University, Bilaspur-495 009, Chhattisgarh, India

Search for more papers by this author

Ravichandran Veerasamy

https://orcid.org/0000-0001-9903-8890

Faculty of Pharmacy, AIMST University, Semeling, 08100 Bedong, Kedah Darul Aman, Malaysia

Search for more papers by this author

Prabodh C Sharma

https://orcid.org/0000-0003-1920-3855

Institute of Pharmaceutical Sciences, Kurukshetra University, Kurukshetra-136 119, Haryana, India

Search for more papers by this author

Harish Rajak

*Author for correspondence:

E-mail Address: harishdops@yahoo.co.in

https://orcid.org/0000-0003-2008-2827

Institute of Pharmaceutical Sciences, Guru Ghasidas University, Bilaspur-495 009, Chhattisgarh, India

Search for more papers by this author

Published Online:20 Aug 2020https://doi.org/10.2217/fon-2020-0385

View article

Abstract

HDAC inhibitors (HDACi) play an essential role in various cellular processes, such as differentiation and transcriptional regulation of key genes and cytostatic factors, cell cycle arrest and apoptosis that facilitates the targeting of epigenome of eukaryotic cells. In the majority of cancers, only a handful of patients receive optimal benefit from chemotherapeutics. Additionally, there is emerging interest in the use of HDACi to modulate the effects of ionizing radiations. The use of HDACi with radiotherapy, with the goal of reaching dissimilar, often distinct pathways or multiple biological targets, with the expectation of synergistic effects, reduced toxicity and diminished intrinsic and acquired resistance, conveys an approach of increasing interest. In this review, the clinical potential of HDACi in combination with radiotherapy is described as an efficient synergy for cancer treatment will be overviewed.

Keywords:

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

1. Park SY, Kim JS. A short guide to histone deacetylases including recent progress on class II enzymes. Exp. & Mol. Med. 52(2), 204–212 (2020). • This paper highlighted the acetylation and deacetylation mechanism of histone proteins in gene expression and translational modifications.
Medline CASGoogle Scholar
2. Gennaro ED, Bruzzese F, Caraglia M, Abruzzese A, Budillon A. Acetylation of proteins as novel target for antitumor therapy: review article. Amino Acids 26(4), 435–441 (2004).
MedlineGoogle Scholar
3. Vahid F, Zand H, Mirshekarlou EN, Najafi R, Hekmatdoost A. The role dietary of bioactive compounds on the regulation of histone acetylases and deacetylases: a review. Gene 562(1), 8–15 (2015).
Medline CASGoogle Scholar
4. Rajak H, Singh A, Raghuwanshi K et al. A structural insight into hydroxamic acid based histone deacetylase inhibitors for the presence of anticancer activity. Curr. Med. Chem. 21(23), 2642–2664 (2014).
Medline CASGoogle Scholar
5. Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of an epigenetic (and more) treatments for cancer. Nature Rev. Cancer 6(1), 38–51 (2006).
Medline CASGoogle Scholar
6. Taunton J, Hassig CA, Schreiber SL. A mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3p. Science 272(5260), 408–409 (1996).
Medline CASGoogle Scholar
7. Mahlknecht U, Hoelzer D. Histone acetylation modifiers in the pathogenesis of malignant disease. Mol. Med. 6(8), 623–624 (2000). • This paper emphasized brief classification of HDAC enzymes and inhibitors and their role in cancer treatment.
Medline CASGoogle Scholar
8. Watson PJ, Fairall L, Santos GM, Schwabe JW. Structure of HDAC3 bound to co-repressor and inositol tetraphosphate. Nature 481, 335–340 (2012).
Medline CASGoogle Scholar
9. Muslin AJ, Xing H. 14-3-3 proteins: regulation of subcellular localization by molecular interference. Cell Signal 12, 703–709 (2000).
Medline CASGoogle Scholar
10. Gao L, Cueto MA, Asselbergs F, Atadja P. Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylasefamily. J. Biol. Chem. 277, 25748–25755 (2002).
Medline CASGoogle Scholar
11. Patel P, Singh A, Patel VK et al. Pharmacophore based 3D-QSAR, virtual screening and docking studies on novel series of HDAC inhibitors with thiophene linker as anticancer agents. Comb. Chem. & High Throughput Screen. 19(9), 735–751 (2016).
Medline CASGoogle Scholar
12. Brachmann CB, Sherman JM, Devine SE, Cameron EE, Pillus L, Boeke JD. The SIR2 gene family, conserved from bacteria to humans, functions in silencing, cell cycle progression, and chromosome stability. Genes Dev. 9(23), 2888–2902 (1995).
Medline CASGoogle Scholar
13. National Cancer Institute. Types of cancer treatment. www.cancer.gov/about-cancer/treatment/types
Google Scholar
14. Yang F, Zhao N, Ge D, Chen Y. Next-generation of selective histone deacetylase inhibitors. RSC Adv. 9, 19571–19583 (2019).
CASGoogle Scholar
15. Wagner FF, Weaver M, Lewis MC, Holson EB. Small molecules inhibitors of zinc-dependent histone deacetylases. Neurotherapeutics 10, 589–604 (2013).
Medline CASGoogle Scholar
16. Cappellacci L, Perinelli DR, Maggi F, Grifantini M, Petrelli R. Recent progress in histone deacetylase inhibitors as anticancer agents. Curr. Med. Chem. 27(15), 2449 –2493 (2020).
Medline CASGoogle Scholar
17. Day JA, Cohen SM. Investigating the selectivity of metalloenzyme inhibitors. J. Med. Chem. 56, 7997–8007 (2013).
Medline CASGoogle Scholar
18. Eckschlager T, Plch J, Stiborova M, Hrabeta J. Histone deacetylase inhibitors as anticancer drugs. Int. J. Mol. Sci. 18(7), 1414 (2017).
Google Scholar
19. Mann BS, Johnson JR, Cohen MH, Justice R, Pazdur R. FDA approval summary: Vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 12(10), 1247–1252 (2007).
Medline CASGoogle Scholar
20. Grant C, Rahman F, Piekarz R et al. Romidepsin: A new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors. Expert Rev. Anticancer Ther. 11, 1622 (2011).
Google Scholar
21. Chien W, Lee DH, Zheng Y et al. Growth inhibition of pancreatic cancer cells by histone deacetylase inhibitor Belinostat through suppression of multiple pathways including HIF, NFkB, and mTOR signaling in vitro and in vivo. Mol. Carcinog. 53, 722–735 (2014).
Medline CASGoogle Scholar
22. Sivaraj D, Green MM, Gasparetto C. Panobinostat for the management of multiple myeloma. Future Oncol. 13, 477–488 (2017).
CASGoogle Scholar
23. Arrowsmith CH, Bountra C, Fish PV, Lee K, Schapira M. Epigenetic protein families: a new frontier for drug discovery. Nat. Rev. Drug Discovery 11, 384–400 (2012).
Medline CASGoogle Scholar
24. Shirbhate E, Sahu D, Patel P et al. Searching for potential HDAC2 inhibitors: structure-activity relationship studies on indole-based hydroxamic acids as an anticancer agent. Lett. Drug Des. Discov. 17(7), 905–917 (2020).
CASGoogle Scholar
25. Carafa V, Miceli M, Altucci L, Nebbioso A. Histone deacetylase inhibitors: a patent review (2009–2011). Expert Opin. Ther. Pat. 23, 1–17 (2013).
Medline CASGoogle Scholar
26. Laubach JP, San-Miguel JF, Hungria V et al. Deacetylase inhibitors: An advance in myeloma therapy? Expert Rev. Hematol. 10(3), 229–237 (2017).
Medline CASGoogle Scholar
27. Micelli C, Rastelli G. Histone deacetylases: structural determinants of inhibitor selectivity. Drug Discov. Today 20, 718–735 (2015).
Medline CASGoogle Scholar
28. Juliandi B, Abematsu M, tsukasa S, Tsujimura K, Smith A, Nakashima K. Induction of superficial cortical layer neurons from mouse embryonic stem cells by valproic acid. Neurosci. Res. 72(1), 23–31 (2012).
Medline CASGoogle Scholar
29. Zhan P, Itoh Y, Suzuki T, Liu X. Strategies for the discovery of target-specific or isoform-selective modulators. J. Med. Chem. 58, 7611–7633 (2015). •• The paper revealed currently available rational design tactics for acquiring class- and isoform-selective inhibitors.
Medline CASGoogle Scholar
30. Pommier Y, Sordet O, Antony S, Hayward RL, Kohn KW. Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks. Oncogene 23(16), 2934–2949 (2004).
Medline CASGoogle Scholar
31. Powis G, Mustacich D, Coon A. The role of the redox protein thioredoxin in cell growth and cancer. Free Radic. Biol. Med. 29(3), 312–322 (2000).
Medline CASGoogle Scholar
32. Chung YM, Yoo YD, Park JK, Kim YT, Kim HJ. Increased expression of peroxiredoxin II confers resistance to cisplatin. Anticancer Res. 21(2A), 1129–1133 (2001).
Medline CASGoogle Scholar
33. Robey RW, Chakraborty AR, Basseville A et al. Histone deacetylase inhibitors: emerging mechanisms of resistance. Mol. Pharm. 8(6), 2021–2031 (2011).
Medline CASGoogle Scholar
34. Fantin VR, Richon VM. Mechanisms of resistance to histone deacetylase inhibitors and their therapeutic implications. Clin. Cancer Res. 13(24), 7237–7242 (2007).
Medline CASGoogle Scholar
35. Nolan L, Johnson PW, Ganesan A, Packham G, Crabb SJ. Will histone deacetylase inhibitors require combination with other agents to fulfil their therapeutic potential? Br. J. Cancer 99(5), 689–694 (2008).
Medline CASGoogle Scholar
36. Lindemann RK, Gabrielli B, Johnstone RW. Histone-deacetylase inhibitors for the treatment of cancer. Cell Cycle 3(6), 777–786 (2004).
Google Scholar
37. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat. Rev. Drug Discov. 5(9), 769–784 (2006).
Medline CASGoogle Scholar
38. Suraweera A, O'Byrne KJ, Richard DJ. Combination therapy with histone deacetylase inhibitors (HDACi) for the treatment of cancer: achieving the full therapeutic potential of HDACi. Front. Oncol. 8, 1–15 (2018).
MedlineGoogle Scholar
39. Chinnaiyan P, Vallabhaneni G, Armstrong E, Huang SM, Harari PM. Modulation of radiation response by histone deacetylase inhibition. Int. J. Radiat. Oncology Biol. Phys. 62(1), 223–229 (2005).
Medline CASGoogle Scholar
40. Delaney G, Jacob S, Featherstone C, Barton M. The role of radiotherapy in cancer treatment:estimating optimal utilization from a review of evidence-based clinical guidelines. Cancer 104, 1129–1137 (2005).
MedlineGoogle Scholar
41. O'Sullivan B, Waldron J. Principles in radiation oncology. Wiley, NY, USA (2004).
Google Scholar
42. Lyubimova NV, Coultas PG, Yuen K, Martin RF. In vivo radioprotection of mouse brainendothelial cells by Hoechst 33342. Br. J. Radiol. 74, 77–82 (2001).
Medline CASGoogle Scholar
43. Camphausen K, Tofilon PJ. Inhibition of histone deacetylation: a strategy for tumor radiosensitization. J. Clin. Oncol. 25, 4051–4060 (2007).
Medline CASGoogle Scholar
44. Camphausen K, Cerna D, Scott T et al. Enhancement of in vitro and in vivo tumor cell radiosensitivity by valproic acid. Int. J. Cancer 114(3), 380–386 (2005).
Medline CASGoogle Scholar
45. Camphausen K, Burgan W, Cerra M et al. Enhanced radiation-induced cell killing and prolongation of gamma H2AX foci expression by the histone deacetylase inhibitor MS-275. Cancer Res. 64(1), 316–321 (2004).
Medline CASGoogle Scholar
46. Kim JH, Shin JH, Kim IH. Susceptibility and radiosensitization of human glioblastoma cells to trichostatin A, a histone deacetylase inhibitor. Int. J. Radiat. Oncol. Biol. Phys. 59, 1174–1180 (2004).
Medline CASGoogle Scholar
47. Zhang Y, Jung M, Dritschilo A, Jung M. Enhancement of radiation sensitivity of human squamous carcinoma cells by histone deacetylase inhibitors. Radiat. Res. 161(6), 667–674 (2004).
Medline CASGoogle Scholar
48. Geng L, Cuneo KC, Fu A, Tu T, Atadja PW, Hallahan DE. Histone deacetylase (HDAC) inhibitor LBH589 increases duration of gamma-H2AX foci and confines HDAC4 to the cytoplasm in irradiated non-small cell lung cancer. Cancer Res. 66(23), 11298–11304 (2006).
Medline CASGoogle Scholar
49. Folkvord S, Ree AH, Furre T, Halvorsen T, Flatmark K. Radiosensitization by SAHA in experimental colorectal carcinoma models – in vivo effects and relevance of histone acetylation status. Int. J. Radiat. Oncol. Biol. Phys. 74(2), 546–552 (2009).
Medline CASGoogle Scholar
50. Chen X, Wong P, Radany E, Wong JYC. HDAC inhibitor, valproic acid, induces p53-dependent radiosensitization of colon cancer cells. Cancer Biother. Radiopharm. 24(6), 689–699 (2009).
Medline CASGoogle Scholar
51. Camphausen K, Scott T, Sproull M, Tofilon PJ. Enhancement of xenograft tumor radiosensitivity by the histone deacetylase inhibitor MS-275 and correlation with histone hyperacetylation. Clin. Cancer Res. 10(18), 6066–6071 (2004).
Medline CASGoogle Scholar
52. Munshi A, Kurland JF, Nishikawa T et al. Histone deacetylase inhibitors radiosensitize human melanoma cells by suppressing DNA repair activity. Clin. Cancer Res. 11(13), 4912–4922 (2005).
Medline CASGoogle Scholar
53. Baschnagel A, Russo A, Burgan WE et al. Vorinostat enhances the radiosensitivity of a breast cancer brain metastatic cell line grown in vitro and as intracranial xenografts. Mol. Cancer Ther. 8(6), 1589–1595 (2009).
Medline CASGoogle Scholar
54. Dong Q, Sharma S, Liu H et al. HDAC inhibitors reverse acquired radio resistance of KYSE-150R esophageal carcinoma cells by modulating Bmi-1 expression. Toxicology Lett. 224, 121–129 (2014).
Medline CASGoogle Scholar
55. Moertl S, Payer S, Kell R, Winkler K, Anastasov N, Atkinson MJ. Comparison of radiosensitization by HDAC inhibitors CUDC-1010 and SAHA in pancreatic cancer cells. Int. J. Mol. Sci. 20, 3259 (2019).
CASGoogle Scholar
56. Rogakou EP, Pilch DR, Orr AH, Ivanova VS, Bonner WM. DNA-double strand breaks induce histone H2AX phosphorylation on serine 139. J. Biol. Chem. 273(10), 5858–5868 (1998).
Medline CASGoogle Scholar
57. Munshi A, Tanaka T, Hobba ML, Tucker SL, Richon VM, Meyn RE. Vorinostat, a histone deacetylase inhibitor enhances the response of human tumor cells to ionizing radiation through prolongation of gamma-H2AX foci. Mol. Cancer Ther. 5(8), 1967–1974 (2006).
Medline CASGoogle Scholar
58. Zhang Y, Adachi M, Zhao X, Kawamura R, Imai K. Histone decetylase inhibitors FK228,N-(2-aminophenyl)-4-[N-(pyridine-3-ylmethoxycarbonyl)amino-methyl]benzamide and m-carboxycinnamic acid bishydroxamide augment radiation-induced cell death in gastrointestinal adenocarcinoma cells. Int. J. Cancer 110(2), 301–380 (2004).
Medline CASGoogle Scholar
59. Shabason JE, Tofilon PJ, Camphausen K. Grand rounds at the National Institutes of Health: HDAC inhibitors as radiation modifiers, from bench to clinic. J. Cell. Mol. Med. 15, 2735–2744 (2011).
MedlineGoogle Scholar
60. Blattmann C, Oertel S, Ehemann V et al. Enhancement of radiation response in osteosarcoma and rhabdomyosarcoma cell lines by histone deacetylase inhibition. Int. J. Radiat. Oncol. Biol. Phys. 78(1), 237–245 (2010).
Medline CASGoogle Scholar
61. Kao GD, McKenna WG, Guenther MG, Muschel RJ, Lazar MA, Yen TJ. Histone deacetylase 4 interacts with 53BP1 to mediate the DNA damage response. J. Cell Biol. 160, 1017–1027 (2003).
Medline CASGoogle Scholar
62. Storch K, Eke I, Borgmann K et al. Three-dimensional cell growth confers radioresistance by chromatin density modification. Cancer Res. 70(10), 3925–3934 (2010).
Medline CASGoogle Scholar
63. Groselj B, Sharma NL, Hamdy FC, Kerr M, Kiltie AE. Histone deacetylase inhibitors as radiosensitizers: effects on DNA damage signaling and repair. Br. J. Cancer 108, 748–754 (2013).
Medline CASGoogle Scholar
64. Ree AH, Dueland S, Folkvord S et al. Vorinostat, a histone deacetylase inhibitor, combined with pelvic palliative radiotherapy for gastrointestinal carcinoma: The Pelvic Radiation and Vorinostat (PRAVO) phase 1 study. Lancet Oncol. 11(5), 459–464 (2010).
Medline CASGoogle Scholar
65. Thurn KT, Thomas S, Moore A, Munster PN. Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer. Future Oncol. 7(2), 263–283 (2011). •• This paper demonstrated the rationale and clinical progress of various combinations of HDACi with other chemotherapeutic drugs along with future therapeutic uses of HDACi for treatment of cancer.
CASGoogle Scholar
66. Kuribayashi T, Ohar M, Sora S, Kubota N. Scriptaid, a novel histonedeacetylase inhibitor, enhances the response of human tumor cells to radiation. Int. J. Mol. Med. 25(1), 25–29 (2010).
Medline CASGoogle Scholar
67. Zhang Y, Manfred J, Dritschiloa A, Junga M. Enhancement of radiation sensitivity of human squamous carcinoma cells by histone deacetylase inhibitors. Rad. Res. 161, 667–674 (2004).
Medline CASGoogle Scholar
68. Xaio W, Graham PH, Hao J et al. Combination therapy with the histone deacetylase inhibitor LBH589 and radiation is an effective regimen for prostate cancer cells. PLoS One 8(8), 1–14 (2013).
Google Scholar
69. Groselj B, Ruan JL, Scott H et al. Radiosensitization in vivo by histone deacetylase inhibition with no increase in early normal tissue radiation toxicity. Mol. Cancer Ther. 17(2), 381–392 (2018).
Medline CASGoogle Scholar
70. Santini V, Gozzini A, Ferrari G. Histone deacetylase inhibitors: molecular and biological activity as a premise to clinical application. Curr. Drug Met. 8, 383–394 (2007).
Medline CASGoogle Scholar
71. Banuelos CA, Banath JP, MacPhail SH, Zhao J, Reitsema T, Olive PL. Radiosensitization by the histone deacetylase inhibitor PCI-24781. Clin. Cancer Res. 13(22), 6816–6825 (2007).
Medline CASGoogle Scholar
72. Chen X, Wong P, Radany E, Wong J. HDAC inhibitor, valproic acid, induces p53-dependent radiosensitization of colon cancer cells. Cancer Biother. Radiopharm. 24(6), 689–699 (2009).
Medline CASGoogle Scholar
73. Hosein AN, Lim YC, Day B et al. The effect of valproic acid in combination with irradiation and temozolomide on primary human Glioblastoma cells. J. Neurooncol. 122(2), 263–271 (2015).
Medline CASGoogle Scholar
74. Tofilon PJ, Camphausen KA. HDAC inhibitors in cancer care. Oncol. J. 24, 1–9 (2010).
Google Scholar
75. Noguchi H, Yamashita H, Murakami T et al. Successful treatment of anaplastic thyroid carcinoma with a combination of oral valproic acid, chemotherapy, radiation and surgery. Endocrine J. 56(2), 245–249 (2009).
MedlineGoogle Scholar
76. Karagiannis TC, El-Osta A. Review: modulation of cellular radiation responses by histone deacetylase inhibitors. Oncogene 25, 3885–3893 (2006).
Medline CASGoogle Scholar
77. Suraweera A, O'Byrne KJ, Richard DJ. Combination therapy with histone deacetylase inhibitors (HDACi) for the treatment of cancer: achieving the full therapeutic potential of HDACi. Front. Oncol. 8, 92 (2018). •• This paper demonstrated the combination of HDACi with other anticancer agents and their possibilities for conversion into preclinical and clinical investigations.
MedlineGoogle Scholar
78. Miller CP, Singh MM, Rivera-Del NV, Manton CA, Chandra J. Therapeutic strategies to enhance the anticancer efficacy of histone deacetylase inhibitors. J. Biomed. Biotech. doi:10.1155/2011/514261 (2011).
Google Scholar
79. Karagiannis T, El-Osta A. Clinical potential of histone deacetylase inhibitors as standalone therapeutics and in combination with other chemotherapeutics or radiotherapy for cancer. Epigenetics 1(3), 121–126 (2006).
MedlineGoogle Scholar
80. Zhang F, Zhang T, Teng ZH, Zhang R, Wang JB, Mei QB. Sensitization to γ-irradiation induced cell cycle arrest and apoptosis by the histone deacetylase inhibitor trichostatin A in non-small cell lung cancer (NSCLC) cells. Cancer Biol. Ther. 8(9), 823–831 (2009).
Medline CASGoogle Scholar
81. Choi CYH, Wakelee HA, Neal JW et al. Vorinostat and concurrent stereotactic radiosurgery for non–small cell lung cancer brain metastases: A phase 1 dose escalation trial. Int. J. Radiat. Oncol. Biol. Phys. 99(1), 16–21 (2017).
Medline CASGoogle Scholar
82. Perona M, Thomasz L, Rossich L et al. Radiosensitivity enhancement of human thyroid carcinoma cells by the inhibitors of histone deacetylase sodium butyrate and valproic acid. Mol. Cell Endrocrinol. 478, 141–150 (2018).
Medline CASGoogle Scholar
83. Paillas S, Then CK, Kilgas S et al. The histone deacetylase inhibitor Romidepsin spares normal tissues while acting as an effective radiosensitizer in bladder tumors in vivo. Int. J. Radiat. Oncol. Biol. Phys. 107(1), 212–221 (2020).
MedlineGoogle Scholar
84. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Drug Discov. 5, 769–784 (2006).
CASGoogle Scholar
85. Johnstone RW. Histone-deacetylase inhibitors: Novel drugs for the treatment of cancer. Drug Discov. 1, 287–299 (2002).
CASGoogle Scholar
86. Rosse G. Novel and selective inhibitors of histone deacetylase. ACS Med. Chem. Lett. 3, 879–880 (2012).
Medline CASGoogle Scholar
87. Sharda A, Rashid M, Shah SG et al. Elevated HDAC activity and altered histone phosphoacetylation confer acquired radio-resistant phenotype to breast cancer cells. Clin Epigenetics 12(1), 4 (2020).
MedlineGoogle Scholar
88. Zhang M, Hu C, Moses N et al. HDAC6 regulates DNA damage response via deacetylating MLH1. J. Biol. Chem. 294(15), 5813–5826 (2019).
Medline CASGoogle Scholar
89. Sferra R, Pompili S, Festuccia C et al. the possible prognostic role of histone deacetylase and transforming growth factor factor β/Smad signaling in high grade gliomas treated by radio-chemotherapy: a preliminary immunohistochemical study. Eur. J. Histochem. 61(2), 86–95 (2017).
Google Scholar
90. Marampon F, Megiomi F, Camero S et al. HDAC4 and HDAC6 sustain DNA double strand break repair and stem-like phenotype by promoting radio resistance in glioblastoma cells. Cancer Lett. 397, 1–11 (2017).
Medline CASGoogle Scholar
91. Yang W, Liu Yingying, Gao R, Tu H, Sun T. HDAC6 inhibition induces glioma stem cells differentiation and enhances radiation sensitivity through the SHH/Gli1 signaling pathway. Cancer Lett. 415, 164–176 (2018)
Medline CASGoogle Scholar
92. Oronsky B, Scicinski J, Kim MM et al. Turning on the radio: epigenetic inhibitors as potential radiopromising agents. Biomol. 6, 32 (2016).
Google Scholar

Vol. 16, No. 30

Metrics

Downloaded 239 times

History

Received 21 April 2020

Accepted 3 July 2020

Published online 20 August 2020

Published in print October 2020

Information

Keywords

Financial & competing interests disclosure

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.

PDF download